These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1141 related items for PubMed ID: 24081937

  • 21. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C, Poggi G, Missale G, Fanello S, Salvagni S, Ardizzoni A, Maria SE.
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [Abstract] [Full Text] [Related]

  • 22. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A.
    Oncology; 2010 Aug; 79(1-2):85-92. PubMed ID: 21071995
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I.
    J Clin Oncol; 2014 Jan 10; 32(2):76-82. PubMed ID: 24323035
    [Abstract] [Full Text] [Related]

  • 27. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W, Zhong H, Kong W, Dong B, Chen Y, Zhou L, Xue W, Huang Y, Zhang J, Huang J.
    Int Urol Nephrol; 2017 Nov 10; 49(11):1955-1963. PubMed ID: 28889323
    [Abstract] [Full Text] [Related]

  • 28. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
    Abdel-Rahman O.
    J Cancer Res Clin Oncol; 2018 May 10; 144(5):901-908. PubMed ID: 29455421
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    Ziogas DC, Papadatos-Pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O'Grady J, Al-Khadimi G, Allen N, Heaton N, Ross PJ, Sarker D.
    Eur J Gastroenterol Hepatol; 2017 Jan 10; 29(1):48-55. PubMed ID: 27623000
    [Abstract] [Full Text] [Related]

  • 30. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul 10; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 31. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 10; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.
    Chin Med Sci J; 2014 Mar 10; 29(1):7-14. PubMed ID: 24698672
    [Abstract] [Full Text] [Related]

  • 34. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
    Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W.
    Ann Oncol; 2016 Apr 10; 27(4):680-7. PubMed ID: 26802147
    [Abstract] [Full Text] [Related]

  • 35. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, Czech Renal Cancer Cooperative Group.
    Ann Oncol; 2012 Dec 10; 23(12):3137-3143. PubMed ID: 22700990
    [Abstract] [Full Text] [Related]

  • 36. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Dec 10; 32(6):705-10. PubMed ID: 25376287
    [Abstract] [Full Text] [Related]

  • 37. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ, Kim SS, Nam JS, Oh MJ, Kang DR, Kim JK, Lee JH, Kim B, Yang MJ, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY.
    Cytokine; 2017 Jul 10; 95():118-125. PubMed ID: 28260649
    [Abstract] [Full Text] [Related]

  • 38. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.
    J Clin Gastroenterol; 2014 Mar 10; 48(3):e22-9. PubMed ID: 24045282
    [Abstract] [Full Text] [Related]

  • 39. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Mar 10; 32(6):733-9. PubMed ID: 25376291
    [Abstract] [Full Text] [Related]

  • 40. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H.
    PLoS One; 2016 Mar 10; 11(1):e0146456. PubMed ID: 26745625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.